PURPOSE: We sought to determine antireflux and asthma medication use after Nissen fundoplication (NF). METHODS: We performed a retrospective study using hospital discharge and pharmacy data from 1996 through 2005. A total of 342 pediatric patients had ≥1 NF; 336 of those had complete medication data. Use of antireflux medications and asthma medications were reviewed before and after NF. RESULTS: Short-term (one year after NF) use of antireflux medications decreased (odds ratio [OR] = 0.35; 95% confidence interval [CI], 0.26-0.45). During the entire study period, the decrease in antireflux medication use after NF remained in place (233 to 197 patients; OR = 0.63; 95% CI, 0.47-0.84). Use of antireflux medications decreased in neurologically healthy patients (n = 186) after NF but remained the same in neurologically impaired patients. Short-term use of inhaled and systemic asthma medications did not change (OR = 1.16 [95% CI, 0.89-1.51] and 0.90 [95% CI, 0.69-1.18]), respectively. During the entire study period, inhaled and systemic asthma medication use increased after NF (OR = 2.11 [95% CI, 1.63-2.74] and 1.85 [95% CI, 1.43-2.41]), respectively. Inhaled and systemic asthma medication use increased in both neurologically healthy and impaired children. In older children (age >5 years), short-term use of inhaled and systemic asthma medications decreased after NF (OR = 0.39 [95% CI, 0.25-0.60] and 0.31 [95% CI, 0.19-0.53]), respectively. However, during the entire study period, inhaled and systemic asthma medication use in older children remained the same. CONCLUSION: NF decreased antireflux medication use in the short and long term, particularly in neurologically healthy children. Inhaled and systemic asthma medication use increased after NF in neurologically healthy and impaired children. NF provided a short-term decrease in inhaled and systemic asthma medication use in older children but showed no change in the long term.
PURPOSE: We sought to determine antireflux and asthma medication use after Nissen fundoplication (NF). METHODS: We performed a retrospective study using hospital discharge and pharmacy data from 1996 through 2005. A total of 342 pediatric patients had ≥1 NF; 336 of those had complete medication data. Use of antireflux medications and asthma medications were reviewed before and after NF. RESULTS: Short-term (one year after NF) use of antireflux medications decreased (odds ratio [OR] = 0.35; 95% confidence interval [CI], 0.26-0.45). During the entire study period, the decrease in antireflux medication use after NF remained in place (233 to 197 patients; OR = 0.63; 95% CI, 0.47-0.84). Use of antireflux medications decreased in neurologically healthy patients (n = 186) after NF but remained the same in neurologically impaired patients. Short-term use of inhaled and systemic asthma medications did not change (OR = 1.16 [95% CI, 0.89-1.51] and 0.90 [95% CI, 0.69-1.18]), respectively. During the entire study period, inhaled and systemic asthma medication use increased after NF (OR = 2.11 [95% CI, 1.63-2.74] and 1.85 [95% CI, 1.43-2.41]), respectively. Inhaled and systemic asthma medication use increased in both neurologically healthy and impaired children. In older children (age >5 years), short-term use of inhaled and systemic asthma medications decreased after NF (OR = 0.39 [95% CI, 0.25-0.60] and 0.31 [95% CI, 0.19-0.53]), respectively. However, during the entire study period, inhaled and systemic asthma medication use in older children remained the same. CONCLUSION: NF decreased antireflux medication use in the short and long term, particularly in neurologically healthy children. Inhaled and systemic asthma medication use increased after NF in neurologically healthy and impaired children. NF provided a short-term decrease in inhaled and systemic asthma medication use in older children but showed no change in the long term.
Authors: R H Pearl; D K Robie; S H Ein; B Shandling; D E Wesson; R Superina; K Mctaggart; V F Garcia; J A O'Connor; R M Filler Journal: J Pediatr Surg Date: 1990-11 Impact factor: 2.545
Authors: Diego M Diaz; Harland S Winter; Richard B Colletti; George D Ferry; Colin D Rudolph; Steven J Czinn; William Cochran; Benjamin D Gold Journal: J Pediatr Gastroenterol Nutr Date: 2007-07 Impact factor: 2.839
Authors: E W Fonkalsrud; K W Ashcraft; A G Coran; D G Ellis; J L Grosfeld; W P Tunell; T R Weber Journal: Pediatrics Date: 1998-03 Impact factor: 7.124
Authors: S J Spechler; E Lee; D Ahnen; R K Goyal; I Hirano; F Ramirez; J P Raufman; R Sampliner; T Schnell; S Sontag; Z R Vlahcevic; R Young; W Williford Journal: JAMA Date: 2001-05-09 Impact factor: 56.272